Jasper Therapeutics Experiences Promising Q2 2025 Results Despite Challenges

Jasper Therapeutics reported Q2 2025 results, highlighting promising efficacy data from the BEACON and SPOTLIGHT studies for its briquilimab therapy. The company reported a net loss of $26.7 million, with cash reserves totaling $39.5 million. Jasper is addressing product lot variability issues and plans to initiate a Phase 2b study in mid-2026.

Title: Jasper Therapeutics Reports Q2 2025 Results, Highlights Efficacy Data for Briquilimab

Jasper Therapeutics, Inc. (NASDAQ: JSPR) reported its second-quarter 2025 financial results and provided an update on the efficacy of its briquilimab therapy, targeting mast cell-driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The company reported a net loss of $26.7 million, with a cash position of $39.5 million.

The company highlighted promising efficacy data from the BEACON and SPOTLIGHT studies. In the BEACON study, briquilimab demonstrated a complete response rate of 89% in CSU patients across 240mg and 360mg single-dose cohorts. Additionally, 92% of CIndU patients in the 180mg SPOTLIGHT cohort showed complete responses. These results reinforce the potential of briquilimab as a highly differentiated therapy in mast cell-driven diseases.

However, Jasper is investigating anomalous results in two BEACON study cohorts where 11 of 13 patients showed no UAS7 reduction, potentially due to product lot variability. The company is pursuing various avenues of investigation and plans to provide an update on the status of the investigation later this year. Despite these issues, Jasper has not observed any dose-limiting safety signals and plans to redose patients with drug product from a different lot and enroll additional patients across those cohorts, with data expected to be reported in late 2025.

Jasper has also implemented a 50% workforce reduction to focus on its urticaria programs. The company's planned Phase 2b CSU study, originally scheduled for mid-2025, has been delayed to mid-2026.

Overall, while Jasper Therapeutics faces challenges, the company's strong efficacy data and focus on its urticaria programs position it well to deliver multiple catalysts that could drive long-term value for stockholders.

References:
1. [https://www.stocktitan.net/news/JSPR/jasper-therapeutics-reports-second-quarter-2025-financial-results-kqbpiywixwc8.html](https://www.stocktitan.net/news/JSPR/jasper-therapeutics-reports-second-quarter-2025-financial-results-kqbpiywixwc8.html)
2. [https://www.morningstar.com/news/globe-newswire/9511863/jasper-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update](https://www.morningstar.com/news/globe-newswire/9511863/jasper-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update)